In the present study, we first found that genetically proxied inhibition of HMG-CoA reductase and NPC1L1 were significantly associated with lower odds of breast cancer (especially ER-positive breast cancer), while the inhibition of PCSK9 was associated with reduced risk of prostate cancer. The gene discussed is NPC1L1; the disease is breast carcinoma.